<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548430</url>
  </required_header>
  <id_info>
    <org_study_id>TTP4000-101</org_study_id>
    <nct_id>NCT01548430</nct_id>
  </id_info>
  <brief_title>A Safety Study of TTP4000 in Subjects With Alzheimer's Disease</brief_title>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Phase 1 Study of 2 Escalating, Single Subcutaneous Doses to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of TTP4000 in Subjects With Alzheimer's Disease With Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>vTv Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>vTv Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the safety, tolerability, immunogenicity and
      pharmacokinetics of TTP4000 in subjects with Alzheimer's disease with mild cognitive
      impairment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participant with adverse events</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of participant plasma TTP4000 concentrations</measure>
    <time_frame>Day 0 to Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>TTP4000 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TTP4000 3.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered subcutaneously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TTP4000</intervention_name>
    <arm_group_label>TTP4000 1.0 mg/kg</arm_group_label>
    <arm_group_label>TTP4000 3.0 mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥ 50 years of age.

          -  Body Mass Index (BMI) of 18 to 35 kg/m2, inclusive.

          -  Weight ≥ 50 kg.

          -  Alzheimer's disease according to the DSM-IV-TR criteria and a score between 20 and 26
             on the Mini Mental State Exam.

          -  Subject must have a medical history for at least 6 months prior to Screening
             (confirmed by medical records) of a diagnosis of mild Alzheimer's disease.

        Exclusion Criteria:

          -  Current evidence or history within the last 3 years of a neurological or psychiatric
             illness that could contribute to dementia, including, but not limited to: epilepsy,
             focal brain lesion, Parkinson's disease, seizure disorder, or head injury with loss of
             consciousness; DSM-IV-TR criteria for any major psychiatric disorder, including
             psychosis, major depression, and bipolar disorder.

          -  Participation and dosing in another clinical trial, involving any marketed or
             investigational drug, within 30 days before Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hernandez, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>TransTech Pharma, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2012</study_first_submitted>
  <study_first_submitted_qc>March 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>February 11, 2015</last_update_submitted>
  <last_update_submitted_qc>February 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

